Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 539-548

  Starska, Katarzyna ^a   Brys, Magdalena ^b   Forma, Ewa ^b   Glowacka, Ewa ^c   Lewy Trenda, Iwona ^a   Stasikowska, Olga ^a   Krajewska, Wanda M ^b   Lukomski, Marek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Epidermal growth factor receptor; Laryngeal carcinoma; Proinflammatory regulatory cytokines; Signal transducer and activator of transcription 3 factor

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; STAT3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGECTOMY; LARYNX CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; BIOSYNTHESIS; CELL MEMBRANE; CYTOPLASM; GENETICS; IMMUNOLOGY; INFLAMMATION; LARYNX TUMOR; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; CYTOKINES; CYTOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR;

EID: 62849087103     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000255     Document Type: Article

References (52)

1. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr and Gutkind JS: Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8: 733-746, 2006.
2. Garcia JA: HIFing the brakes: therapeutic opportunities for treatment of human malignancies. Sci STKE 337: 25, 2006.
3. Kuwahara I, Lillehoj EP, Lu W, Singh IS, Isohama Y, Miyata T and Kim KC: Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-{kappa}B activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 291: L407-L416, 2006.
4. Suzuki S, Igarashi S, Hanawa M, Matsubara H, Ooi A and Dobashi Y: Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Mod Pathol 19: 986-998, 2006.
5. Bentzen SM, Atasoy BM, Daley FM, et al: Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23: 5560-5567, 2005.
6. Kijima T, Niwa H, Steinman RA, et al: STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 13: 355-362, 2002.
7. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
8. Dicker AP and Rodeck U: Predicting the future from trials of the past: epidermal growth factor receptor expression and outcome of fractionated radiation therapy trials. J Clin Oncol 23: 5437-5439, 2005.
9. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
10. Salomon DS, Brandt R, Ciardiello, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
11. Merchant NB, Voskresensky I, Rogers CM, et al: TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 14: 1182-1191, 2008.
12. Révillion F, Lhotellier V, Hornez L, Bonneterre J and Peyrat JP: ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19: 73-80, 2008.
13. Lee JW, Soung YH, Kim SY, et al: Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 2879-2882, 2005.
14. Dowell JE and Minna JD: Chasing mutations in the epidermal growth factor in lung cancer. N Engl J Med 352: 830-832, 2005.
15. Sellers WR and Meyerson M: EGFR gene mutations: a call for global x global views of cancer. J Natl Cancer Inst 97: 326-328, 2005.
16. Haura EB, Turkson J and Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2: 315-324, 2005.
17. Leong PL, Andrews GA, Johnson DE, et al: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100: 4138-4143, 2003.
18. Masuda M, Suzui M, Yasumatu R, et al: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3355, 2002.
19. Gao SP, Mark KG, Lesli K, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856, 2007.
20. Lee TL, Yeh J, Van Waes C and Chen Z: Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/ or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5: 8-19, 2006.
21. Sriuranpong V, Par JI, Amornphimoltham P, Patel V, Nelki BD and Gutkind JS: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63: 2948-2956, 2003.
22. Hirano T, Ishihar K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548-2556, 2000.
23. Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660-3663, 2007.
24. Haura EB, Zhen Z, Son L, Cantor A and Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294, 2005.
25. Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4: 97-105, 2004.
26. Seki Y, Suzuk N, Imaizumi M, Iwamoto T, Usami N, Ueda Y and Hamaguchi M: STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int J Oncol 24: 931-934, 2004.
27. Grandis JR, Drenning SD, Zeng Q, et al: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97: 4227-4232, 2000.
28. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro. J Clin Invest 102: 1385-1392, 1998.
29. Yang JL, Qu XJ, Hayes VM, Brenner PC, Russell PJ and Goldstein D: Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. BJU Int 6: 1539-1545, 2007.
30. Teraishi F, Kagawa S, Watanabe T, et al: ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 579: 4069-4075, 2005.
31. Hambek M, Solbach C, Schnuerch HG, et al: Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 61: 1045-1049, 2001.
32. Perez M, Haschke B and Donato NJ: Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor. Oncogene18: 967-978, 1999.
33. Hoffmann M, Schmidt M and Wels W: Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha. Cancer Immunol Immunother 47: 167-175, 1998.
34. Ueno Y, Sakurai H, Matsuo M, Choo MK, Koizumi K and Saiki I: Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. Br J Cancer 92: 1690-1695, 2005.
35. Ando K, Ohmori T, Inoue F, et al: Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 11: 8872-8879, 2005.
36. Perez M and Donato NJ: Activation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor correlates with loss of cytotoxic activity. J Interferon Cytokine Res 16: 307-314, 1996.
37. Kenny PA and Bissell MJ: Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117: 337-345, 2007.
38. Kenny PA: Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem Soc Trans 35: 665-668, 2007.
39. Zhang Q, Thomas SM, Lui VW, et al: Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci USA 103: 6901-6906, 2006.
40. Wehbe H, Henson R, Meng F, Mize-Berg J and Patel T: Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 66: 10517-10524, 2006.
41. Nakanaga T, Nadel JA, Ueki IF, Koff JL and Shao MX: Regulation of interleukin-8 via an airway epithelial signaling cascade. Am J Physiol Lung Cell Mol Physiol 292: L1289-L1296, 2007.
42. Bancroft CC, Chen Z, Yeh J, et al: Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548, 2002.
43. Sobin LH and Wittekind C (eds): TNM Classification of Malignant Tumours, 6th edition. Wiley J & Sons, Hoboken, NJ, 2002.
44. Fogarty GB, Conus NM, Chu J and McArthur G: Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 156: 92-98, 2007.
45. Cohen D, Lane B, Jin T, et al: The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. Clin Genitourin Cancer 5: 264-270, 2007.
46. Croker BA, Krebs DL, Zhang JG, et al: SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 507-509, 2003.
47. Berishaj M, Gao SP, Ahmed S, et al: Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9: R32, 2007.
48. Kotha A, Sekharam M, Cilenti L, et al: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5: 621-629, 2006.
49. Leslie K, Lang C, Devgan G, et al: Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66: 2544-2552, 2006.
50. Kishimoto T: Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8: S2, 2006.
51. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE and Stark GR: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21: 1396-1408, 2007.
52. Knüpfer H and Preiss R: Significance of interleukin-6 (IL-6) in breast cancer. Breast Cancer Res Treat 102: 129-135, 2007.